Juncell Therapeutics is focused on innovative TIL (tumor-infiltrating lymphocyte) therapies for solid tumors, including both natural TIL programs and non-viral gene-modified TIL programs. Our TIL therapies are featured with an improved safety profile without compromising efficacy, thanks to the enhanced TIL manufactured by DeepTIL® cell expansion platform. DeepTIL® enables TIL to be potent enough so that the high-dose IL-2 combination could be eliminated and the intensity of pretreatment could be much lower. Juncell also established the NovaGMP® non-viral vector gene-modification platform, which is of high efficiency (> 45% in the final cell product) and low cost of goods (< 10% of lentiviral vector). Juncell natural TIL therapy GC101 and gene-engineered TIL therapy GC203 have shown promising efficacy in melanoma, lung cancer, ovarian cancer, pancreatic cancer, cervical cancer, endometrial cancer, bile duct cancer, glioma and breast cancer, including 6 complete responses.